Purine-rich element binding protein alpha: a DNA/RNA binding protein with multiple roles in cancers

Area of Science:

• Molecular Biology
• Cancer Research
• Biochemistry

Background:

• DNA/RNA binding proteins are crucial for gene regulation and are often conserved.
• Dysregulation of these proteins, like purine-rich element binding protein alpha (PURα), contributes to human diseases, particularly cancer.
• PURα has been identified as both a tumor suppressor in acute myeloid leukemia and prostate cancer, and dysregulated in breast and esophageal cancers.

Purpose of the Study:

• To review the multifaceted roles of PURα in various cancer types.
• To explore the potential of PURα as a biomarker and therapeutic target in oncology.
• To summarize recent findings on PURα's involvement in cancer progression and treatment.

Main Methods:

• Literature review of recent studies on PURα in cancer.
• Analysis of PURα's regulatory functions in transcription, translation, RNA stability, and splicing.
• Examination of PURα's role in stress granule formation and RNA/protein interactions.

Main Results:

• PURα exhibits context-dependent oncogenic or tumor-suppressive functions across different cancers.
• PURα influences cancer through regulating mRNA translation, stress granule dynamics, and oncogene/tumor suppressor transcription.
• Novel strategies targeting PURα have shown preclinical anti-tumor efficacy.

Conclusions:

• PURα is a critical regulator in multiple cancer types with significant implications for disease progression.
• PURα represents a promising biomarker and therapeutic target for cancer treatment.
• Further research into PURα-targeting agents could lead to effective anti-cancer therapies.